Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 133

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 20
Venture Financing 22
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 22
Partnerships 23
Ligand Pharma Enters into Agreement with AiCuris 23
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 24
Symphogen Enters Into Agreement With Open Monoclonal Technology 25
Open Monoclonal Expands Agreement with CNA Development 26
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 27
Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 28
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 29
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 30
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 31
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 32
WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 33
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 34
Licensing Agreements 35
Amgen Enters into Licensing Agreement with Ligand Pharma 35
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 36
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 37
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 38
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 39
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 40
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 41
Novartis Enters into Licensing Agreement with Ligand Pharma 42
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 43
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 44
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 45
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 46
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 47
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 48
Sanofi Enters into Licensing Agreement with Ligand Pharma 49
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 50
Open Monoclonal Enters into Licensing Agreement with Celgene 51
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 52
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 53
Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 54
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 56
Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 57
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 58
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 59
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 60
TeneoBio Enters into Licensing Agreement with Ligand Pharma 61
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 62
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 63
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 64
RODES Enters into Licensing Agreement with Ligand Pharma 65
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 66
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 67
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 68
Open Monoclonal Enters into Licensing Agreement with Amgen 69
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 70
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 71
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 72
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 73
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 74
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 75
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 76
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 77
Ligand Pharma Enters Into Licencing Agreement With Merck 78
Ligand Pharma Enters Into Licensing Agreement With Hospira 79
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 80
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 81
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 82
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 83
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 84
Equity Offering 86
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 86
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 87
Debt Offering 88
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 88
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 90
Acquisition 91
Ligand Pharma to Acquire Crystal Bioscience 91
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 93
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 94
Ligand Pharma Acquires CyDex Pharma 95
Ligand Pharmaceuticals Inc - Key Competitors 97
Ligand Pharmaceuticals Inc - Key Employees 98
Ligand Pharmaceuticals Inc - Locations And Subsidiaries 99
Head Office 99
Other Locations & Subsidiaries 99
Recent Developments 101
Financial Announcements 101
Nov 09, 2017: Ligand Reports Third Quarter 2017 Financial Results 101
Aug 07, 2017: Ligand Reports Second Quarter 2017 Financial Results 104
May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 107
Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 110
Nov 03, 2016: Ligand Reports Third Quarter 2016 Financial Results 113
Aug 04, 2016: Ligand Reports Second Quarter 2016 Financial Results 116
May 04, 2016: Ligand Reports First Quarter 2016 Financial Results 119
Feb 10, 2016: Ligand Reports Fourth Quarter and Full Year 2015 Financial Results 122
Corporate Communications 125
Aug 21, 2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors 125
Clinical Trials 126
Feb 27, 2017: Enrollment Completed in Ligand's Phase 2 Trial of LGD-6972 in Type 2 Diabetes 126
Sep 13, 2016: Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes 127
Aug 15, 2016: Results from Phase 1 Trials with Ligand LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism 128
Other Significant Developments 130
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies 130
Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 131
Appendix 133
Methodology 133
About GlobalData 133
Contact Us 133
Disclaimer 133

List of Tables
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 20
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 22
Ligand Pharma Enters into Agreement with AiCuris 23
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 24
Symphogen Enters Into Agreement With Open Monoclonal Technology 25
Open Monoclonal Expands Agreement with CNA Development 26
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 27
Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 28
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 29
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 30
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 31
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 32
WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 33
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 34
Amgen Enters into Licensing Agreement with Ligand Pharma 35
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 36
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 37
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 38
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 39
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 40
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 41
Novartis Enters into Licensing Agreement with Ligand Pharma 42
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 43
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 44
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 45
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 46
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 47
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 48
Sanofi Enters into Licensing Agreement with Ligand Pharma 49
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 50
Open Monoclonal Enters into Licensing Agreement with Celgene 51
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 52
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 53
Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 54
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 56
Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 57
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 58
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 59
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 60
TeneoBio Enters into Licensing Agreement with Ligand Pharma 61
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 62
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 63
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 64
RODES Enters into Licensing Agreement with Ligand Pharma 65
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 66
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 67
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 68
Open Monoclonal Enters into Licensing Agreement with Amgen 69
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 70
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 71
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 72
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 73
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 74
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 75
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 76
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 77
Ligand Pharma Enters Into Licencing Agreement With Merck 78
Ligand Pharma Enters Into Licensing Agreement With Hospira 79
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 80
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 81
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 82
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 83
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 84
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 86
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 87
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 88
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 90
Ligand Pharma to Acquire Crystal Bioscience 91
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 93
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 94
Ligand Pharma Acquires CyDex Pharma 95
Ligand Pharmaceuticals Inc, Key Competitors 97
Ligand Pharmaceuticals Inc, Key Employees 98
Ligand Pharmaceuticals Inc, Subsidiaries 99

List of Figures
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027